About Galactose-1-phosphate uridylyltransferase
Galactose-1-phosphate uridylyltransferase (GALT) is a protein
from Homo sapiens identified by UniProt accession
P07902, 379 residues long.
MolForge cross-references it against 0 known binders and
63 disease associations.
Target properties
| Protein name | Galactose-1-phosphate uridylyltransferase |
| UniProt accession | P07902 |
| Gene | GALT |
| Organism | Homo sapiens |
| Length | 379 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (63)
Diseases linked to this target (Open Targets).
- classic galactosemia · score 0.81
- galactosemia · score 0.79
- genetic disorder · score 0.51
- Cataract · score 0.46
- Intellectual disability · score 0.46
- primary ovarian insufficiency · score 0.34
- blood protein measurement · score 0.32
- interleukin-11 receptor subunit alpha measurement · score 0.21
- chemokine (C-C motif) ligand 27 measurement · score 0.20
- MODY · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P07902-F1 | alphafold | PREDICTED | 91.68 | — |
Amino-acid sequence (379 residues)
MSRSGTDPQQ RQQASEADAA AATFRANDHQ HIRYNPLQDE WVLVSAHRMK RPWQGQVEPQ LLKTVPRHDP LNPLCPGAIR ANGEVNPQYD STFLFDNDFP ALQPDAPSPG PSDHPLFQAK SARGVCKVMC FHPWSDVTLP LMSVPEIRAV VDAWASVTEE LGAQYPWVQI FENKGAMMGC SNPHPHCQVW ASSFLPDIAQ REERSQQAYK SQHGEPLLME YSRQELLRKE RLVLTSEHWL VLVPFWATWP YQTLLLPRRH VRRLPELTPA ERDDLASIMK KLLTKYDNLF ETSFPYSMGW HGAPTGSEAG ANWNHWQLHA HYYPPLLRSA TVRKFMVGYE MLAQAQRDLT PEQAAERLRA LPEVHYHLGQ KDRETATIA
Explore Galactose-1-phosphate uridylyltransferase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets